ChemotherapyFDA-approvedFirst-line
mFOLFOX6
Generic name: oxaliplatin
How it works
Oxaliplatin works by forming platinum-DNA adducts, which interfere with DNA replication and cell division, ultimately leading to cancer cell death.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, mFOLFOX6 improved response rates and survival in patients with metastatic colorectal cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Chemo-Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Lung Perfusion with Oxaliplatin for Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Rectal Cancer Trial Examines New Treatment Combination | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating a Combination Treatment for Metastatic Colorectal Cancer in Elderly Patients | Colorectal Cancer | phase-2 | — | Source → |
| Blueberry Anthocyanins Enhance Chemotherapy Effectiveness in Colon Cancer Cells | Colorectal Cancer | lab-study | The combination of blueberry anthocyanins and oxaliplatin significantly inhibited the proliferation and colony formation of HCT116 and LOVO cells (P<0.01) and markedly suppressed tumor growth in the nude mouse xenograft model (P<0.05). | Source → |
| Oxaliplatin Side Effect Study in Colorectal Cancer Patients | Colorectal Cancer | phase-3 | — | Source → |
| New Treatment Shows Promise for Colorectal Cancer Patients | Colorectal Cancer | phase-1 | Compared with standard therapy, PIPAC-Oxaliplatin was associated with higher median good days at 6 months (181 vs 131 days; p = 0.042) and 1 year (323 vs 131 days; p = 0.032), and longer overall survival (median, 11.3 vs 5.1 months; p = 0.036). | Source → |
| Oxaliplatin Chemotherapy Less Effective in Colorectal Cancer with High WTAP Levels | Colorectal Cancer | lab-study | — | Source → |
| GL-V9 Enhances Effectiveness of Colorectal Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Rare Side Effect of Cancer Drug: Transient Ischemic Attack | Colorectal Cancer | observational | — | Source → |
| Combination Therapy Shows Promise Against Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Chemotherapy Side Effect Causes Loss of Consciousness in Cancer Patient | Colorectal Cancer | observational | — | Source → |
| Study Examines Effectiveness of S-1 and Oxaliplatin in Treating Colorectal Liver Metastases | Colorectal Cancer | phase-2 | The disease-free survival (DFS) at 3 years was 52.9% in the low-dose group. | Source → |
| Researchers Identify Potential Biomarkers for Colorectal Cancer Resistance to Oxaliplatin | Colorectal Cancer | lab-study | — | Source → |
| Chemotherapy Sensitizes Colorectal Cancers to Immunotherapy | Colorectal Cancer | lab-study | — | Source → |
| Researchers Explore New Way to Deliver Cancer Drug | Colorectal Cancer | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.